[ad_1]
Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine launch syndrome and related neurotoxicity in most cancers immunotherapy. Nat Rev Immunol. 2022;22(2):85–96.
Chowell D, Yoo SK, Valero C, Pastore A, Krishna C, Lee M, Hoen D, Shi H, Kelly DW, Patel N, Makarov V, Ma X, Vuong L, Sabio EY, Weiss Okay, Kuo F, Lenz TL, Samstein RM, Riaz N, Adusumilli PS, Balachandran VP, Plitas G, Ari Hakimi A, Abdel-Wahab O, Shoushtari AN, Postow MA, Motzer RJ, Ladanyi M, Zehir A, Berger MF, Gonen M, Morris LGT, Weinhold N, Chan T. A., Improved prediction of immune checkpoint blockade efficacy throughout a number of most cancers sorts. Nat Biotechnol. 2022;40(4):499–506.
Kubli SP, Berger T, Araujo DV, Siu LL, Mak TW. Past immune checkpoint blockade: rising immunological methods. Nat Rev Drug Discov. 2021;20(12):899–919.
Ribas A, Wolchok JD. Most cancers immunotherapy utilizing checkpoint blockade. Science. 2018;359(6382):1350–5.
Han HS, Jeong S, Kim H, Kim HD, Kim AR, Kwon M, Park SH, Woo CG, Kim HK, Lee KH, Web optimization SP, Kang HW, Kim WT, Kim WJ, Yun SJ, Shin EC. TOX-expressing terminally exhausted tumor-infiltrating CD8(+) T cells are reinvigorated by co-blockade of PD-1 and TIGIT in Bladder most cancers. Most cancers Lett. 2021;499:137–47.
McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion throughout power viral An infection and Most cancers. Annu Rev Immunol. 2019;37:457–95.
Arcia-Anaya D, Elliott T. STAT5A antagonizes TOX in CD8(+) T cell exhaustion. Nat Rev Immunol. 2023;23(2):73.
Chen C, Ni X, Jia S, Liang Y, Wu X, Kong D, Ding D. Massively evoking immunogenic cell loss of life by targeted mitochondrial oxidative stress utilizing an AIE Luminogen with a twisted molecular construction. Adv Mater 2019, 31 (52), e1904914.
Finlay D, Cantrell DA. Metabolism, migration and reminiscence in cytotoxic T cells. Nat Rev Immunol. 2011;11(2):109–17.
Chen SW, Zhu SQ, Pei X, Qiu BQ, Xiong D, Lengthy X, Lin Okay, Lu F, Xu JJ, Wu YB. Most cancers cell-derived exosomal circUSP7 induces CD8(+) T cell dysfunction and anti-PD1 resistance by regulating the miR-934/SHP2 axis in NSCLC. Mol Most cancers. 2021;20(1):144.
Kroy DC, Ciuffreda D, Cooperrider JH, Tomlinson M, Hauck GD, Aneja J, Berger C, Wolski D, Carrington M, Wherry EJ, Chung RT, Tanabe KK, Elias N, Freeman GJ, de Kruyff RH, Misdraji J, Kim AY, Lauer GM. Liver surroundings and HCV replication have an effect on human T-cell phenotype and expression of inhibitory receptors. Gastroenterology. 2014;146(2):550–61.
Wu Y, Ju Q, Jia Okay, Yu J, Shi H, Wu H, Jiang M. Correlation between intercourse and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors). Int J Most cancers. 2018;143(1):45–51.
Alfei F, Kanev Okay, Hofmann M, Wu M, Ghoneim HE, Roelli P, Utzschneider DT, von Hoesslin M, Cullen JG, Fan Y, Eisenberg V, Wohlleber D, Steiger Okay, Merkler D, Delorenzi M, Knolle PA, Cohen CJ, Thimme R, Youngblood B, Zehn D. TOX reinforces the phenotype and longevity of exhausted T cells in power viral An infection. Nature. 2019;571(7764):265–9.
Sekine T, Perez-Potti A, Nguyen S, Gorin JB, Wu VH, Gostick E, Llewellyn-Lacey S, Hammer Q, Falck-Jones S, Vangeti S, Yu M, Smed-Sorensen A, Gaballa A, Uhlin M, Sandberg JK, Brander C, Nowak P, Goepfert PA, Worth DA, Betts MR, Buggert M. TOX is expressed by exhausted and polyfunctional human effector reminiscence CD8(+) T cells. Sci Immunol. 2020;5:49.
Wu P, Zhang H, Solar M, Mao S, He Q, Shi Y, Deng Y, Dong Z, Xu Q, Zhao C, Zhang W, Solar B. Manipulating offense and Protection Signaling to Combat Chilly tumors with Service-Free Nanoassembly of Fluorinated Prodrug and siRNA. Adv Mater. 2022;34(38):2203019.
Abdel-Hakeem MS, Manne S, Beltra JC, Stelekati E, Chen Z, Nzingha Okay, Ali MA, Johnson JL, Giles JR, Mathew D, Greenplate AR, Vahedi G, Wherry EJ. Epigenetic scarring of exhausted T cells hinders reminiscence differentiation upon eliminating power antigenic stimulation. Nat Immunol. 2021;22(8):1008–19.
Wang W, Saeed M, Zhou Y, Yang L, Wang D, Yu H. Non-viral gene supply for most cancers immunotherapy. J Gene Med 2019, 21 (7), e3092.
Huang X, Wu G, Liu C, Hua X, Tang Z, Xiao Y, Chen W, Zhou J, Kong N, Huang P, Shi J, Tao W. Intercalation-driven formation of siRNA nanogels for Most cancers Remedy. Nano Lett. 2021;21(22):9706–14.
Wu P, Yin S, Liu T, Ding D, Wang Okay. Constructing-block crosslinking micelles for enhancing mobile transfection of biocompatible polycations. Sci China Mater 2020.
Li Z, Wang Y, Shen Y, Qian C, Oupicky D, Solar M. Focusing on pulmonary Tumor microenvironment with CXCR4-inhibiting nanocomplex to boost anti-PD-L1 immunotherapy. Sci Adv. 2020;6(20):eaaz9240.
Shen W, Wang Q, Shen Y, Gao X, Li L, Yan Y, Wang H, Cheng Y. Inexperienced Tea Catechin dramatically promotes RNAi mediated by low-molecular-weight polymers. ACS Cent Sci. 2018;4(10):1326–33.
Wu P, Zhang H, Yin Y, Solar M, Mao S, Chen H, Deng Y, Chen S, Li S, Solar B. Engineered EGCG-Containing Biomimetic nanoassemblies as efficient supply platform for enhanced Most cancers Remedy. Adv Sci. 2022;9(15):2105894.
Rawangkan A, Wongsirisin P, Namiki Okay, Iida Okay, Kobayashi Y, Shimizu Y, Fujiki H, Suganuma M. Inexperienced Tea Catechin is an alternate Immune checkpoint inhibitor that inhibits PD-L1 expression and lung Tumor development. Molecules. 2018;23(8):2071.
Gao Z, Jia S, Ou H, Hong Y, Shan Okay, Kong X, Wang Z, Feng G, Ding D. An Activatable Close to-Infrared Afterglow Theranostic Prodrug with Self-sustainable magnification impact of immunogenic cell loss of life. Angew Chem Int Ed Engl 2022, 61 (40), e202209793.
Li J, Gao H, Liu R, Chen C, Zeng S, Liu Q, Ding D. Endoplasmic reticulum focused AIE bioprobe as a extremely environment friendly inducer of immunogenic cell loss of life. Sci China Chem. 2020;63(10):1428–34.
Wu P, Luo X, Wu H, Zhang Q, Dai Y, Solar M. Environment friendly and focused chemo-gene supply with self-assembled fluoro-nanoparticles for liver fibrosis remedy and recurrence. Biomaterials. 2020;261:120311.
Xiao YP, Zhang J, Liu YH, Huang Z, Wang B, Zhang YM, Yu XQ. Cross-linked polymers with fluorinated bridges for environment friendly gene supply. J Mater Chem B. 2017;5(43):8542–53.
Yang P, Peng Y, Feng Y, Xu Z, Feng P, Cao J, Chen Y, Chen X, Cao X, Yang Y, Jie J. Immune Cell-Derived Extracellular vesicles – New Methods in Most cancers Immunotherapy. Entrance Immunol. 2021;12:771551.
Lv J, Cheng Y. Fluoropolymers in biomedical purposes: state-of-the-art and future views. Chem Soc Rev. 2021;50(9):5435–67.
Wang M, Liu H, Li L, Cheng Y. A fluorinated dendrimer achieves glorious gene transfection efficacy at extraordinarily low nitrogen to phosphorus ratios. Nat Commun. 2014;5:3053.
Xu J, Lv J, Zhuang Q, Yang Z, Cao Z, Xu L, Pei P, Wang C, Wu H, Dong Z, Chao Y, Wang C, Yang Okay, Peng R, Cheng Y, Liu Z. A basic technique in direction of customized nanovaccines based mostly on fluoropolymers for post-surgical most cancers immunotherapy. Nat Nanotechnol. 2020;15(12):1043–52.
Ren F, Li Z, Li Okay, Zheng X, Shi J, Zhang C, Guo H, Tong B, Xi L, Cai Z, Dong Y. Donor technique for selling nonradiative decay to attain an environment friendly photothermal remedy for treating most cancers. Sci China Chem. 2021;64(9):1530–9.
Shao H, Cheng S, Yao M, Ji X, Zhong H, Wang D, Fan X, Li Q, Zhou J, Zhang Y, Peng F. A pH-response chemotherapy synergistic photothermal remedy for Tumor suppression and bone regeneration by mussel-inspired mg implant. Regen Biomater. 2021;8(6):rbab053.
Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, Sato E, Fukuoka S, Tada Y, Tanaka A, Morikawa H, Kawazoe A, Kinoshita T, Shitara Okay, Sakaguchi S, Nishikawa H. PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of most cancers. Proc Natl Acad Sci U S A. 2019;116(20):9999–10008.
Yu X, Chen L, Liu J, Dai B, Xu G, Shen G, Luo Q, Zhang Z. Immune modulation of liver sinusoidal endothelial cells by melittin nanoparticles suppresses liver Metastasis. Nat Commun 2019, 10 (1).
Yu J, Inexperienced MD, Li S, Solar Y, Journey SN, Choi JE, Rizvi SM, Qin A, Waninger JJ, Lang X, Chopra Z, El Naqa I, Zhou J, Bian Y, Jiang L, Tezel A, Skvarce J, Achar RK, Sitto M, Rosen BS, Su F, Narayanan SP, Cao X, Wei S, Szeliga W, Vatan L, Mayo C, Morgan MA, Schonewolf CA, Cuneo Okay, Kryczek I, Ma VT, Lao CD, Lawrence TS, Ramnath N, Wen F, Chinnaiyan AM, Cieslik M, Alva A, Zou W. Liver Metastasis restrains immunotherapy efficacy by way of macrophage-mediated T cell elimination. Nat Med. 2021;27(1):152–64.
Tune J, Jia X, Ariga Okay. Strategies with Nanoarchitectonics for Small molecules and nanostructures to manage dwelling cells. Small Strategies. 2020;4(10):2000500.
Li Q, Liu J, Fan H, Shi L, Deng Y, Zhao L, Xiang M, Xu Y, Jiang X, Wang G, Wang L, Wang Z. IDO-inhibitor potentiated immunogenic chemotherapy abolishes main Tumor development and eradicates metastatic lesions by concentrating on distinct compartments inside Tumor microenvironment. Biomaterials. 2021;269:120388.
Ni X, Zhang X, Duan X, Zheng HL, Xue XS, Ding D. Close to-Infrared Afterglow luminescent aggregation-Induced Emission dots with Ultrahigh Tumor-to-liver Sign ratio for promoted image-guided Most cancers Surgical procedure. Nano Lett. 2019;19(1):318–30.
Zhao Z, Chen C, Wu W, Wang F, Du L, Zhang X, Xiong Y, He X, Cai Y, Kwok RTK, Lam JWY, Gao X, Solar P, Phillips DL, Ding D, Tang BZ. Extremely environment friendly photothermal nanoagent achieved by harvesting vitality by way of excited-state intramolecular movement inside nanoparticles. Nat Commun. 2019;10(1):768.
Wu Q, Wang Q, Tang X, Xu R, Zhang L, Chen X, Xue Q, Wang Z, Shi R, Wang F, Ju F, Zhang B, Zhou YL. Correlation between sufferers’ age and most cancers immunotherapy efficacy. Oncoimmunology 2019, 8 (4), e1568810.
[ad_2]
